- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Anti-androgens may be used for hyperandrogenism in PCOS when oral contraceptives contraindicated
A recent study has investigated the efficacy and safety of anti-androgen pharmacological agents on endocrine and metabolic features among those with a history of PCOS.
According to the researchers of this study, they have addressed critical gaps in the literature and directly informed the current 2023 update of the International Evidence-based Guideline for managing PCOS.
Based on the review, the guideline recommends that anti-androgen pharmacological agents be considered for treating clinical hirsutism in cases of contraindicated COCP and cosmetic therapies.
It is also mentioned that, where appropriate, using effective contraception is strongly recommended. They noted women should be advised that anti-androgens may cause under-virilisation of a male fetus.
Therefore, the recommendation remains general and should not override clinical judgment with consideration of individual circumstances and perspectives.
This study, "Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials", is conducted by lead researcher Dr Simon Alesi. The co-author is Dr Maria Forslund.
Dr Alesi et al. explained that Anti-androgens and combined oral contraceptive pills (COCPs) may mitigate hyperandrogenism-related symptoms of PCOS.
There needs to be more research to determine their efficacy and safety in PCOS as this background remains unclear and previous reviews have focused on non-PCOS populations. We further investigated the background (to inform the 2023 International Evidence-based Guideline in PCOS) using databases like MEDLINE, Embase, PsycInfo, All EBM reviews, and CINAHL up to 28th June 2023 for relevant RCTs.
The critical points of this study are:
- Researchers identified 1660 studies.
- Twenty-seven articles had 20 unique studies.
- Thirteen studies (n = 961) were pooled in the meta-analysis.
- They included Anti-androgens finasteride, flutamide, spironolactone, or bicalutamide.
- They found a combo of anti-androgens and lifestyle to be superior to a combo of metformin and lifestyle for hirsutism but were not superior to placebo + lifestyle for hirsutism.
- There was more effectiveness with Daily usage compared to the use every three days for managing hirsutism. The levels of androstenedione lowered.
- A combo of anti-androgens, metformin and lifestyle caused lower testosterone than metformin and lifestyle.
- There were no differences in hirsutism when anti-androgens + metformin + lifestyle were compared with either anti-androgens + lifestyle or metformin + lifestyle.
- Combining anti-androgens with COCP caused poorer lipid profiles than COCP ± placebo, with no differences in other outcomes.
They wrote, "Current evidence does not support the use of anti-androgens preferentially to COCPs to treat hyperandrogenism in PCOS. "
As acknowledged, the study was funded by the National Health and Medical Research Council (NHMRC) of Australia Monash University.
They mentioned, "To our knowledge, this is the first systematic review and meta-analysis that has examined the use of anti-androgens specifically in women with PCOS. "
Further reading:
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00339-5/fulltext
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751